PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer

Heidenreich, 2014, EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing and castration resistant prostate cancer, Eur Urol, 65, 467, 10.1016/j.eururo.2013.11.002 Cornford, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer, Eur Urol, 79, 263, 10.1016/j.eururo.2020.09.046 Nishiyama, 2004, Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy, Int J Urol, 11, 735, 10.1111/j.1442-2042.2004.00896.x Bouman-Wammes, 2017, Benefits of using stereotactic body radiotherapy in patients with metachronous oligometastases of hormone-sensitive prostate cancer detected by (18F)fluoromethylcholine PET/CT, Clin Genitourin Cancer., 15, e773, 10.1016/j.clgc.2017.03.009 Ingrosso, 2017, Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience, World J Urol., 35, 45, 10.1007/s00345-016-1860-0 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomised, multicenter phase II trial, J Clin Oncol., 36, 446, 10.1200/JCO.2017.75.4853 Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5 Radwan, 2017, A phase II randomised trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE), BMC Cancer., 17, 453, 10.1186/s12885-017-3455-6 Morigi, 2015, Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy, J Nucl Med., 56, 1185, 10.2967/jnumed.115.160382 Aluwini, 2020, Oligometastatic prostate cancer: results of a Dutch multidisciplinary consensus meeting, Eur Urol Oncol., 3, 231, 10.1016/j.euo.2019.07.010 Vogelius, 2018, Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: A meta-analysis of randomised trials, Int J Radiat Oncol Biol Phys., 100, 858, 10.1016/j.ijrobp.2017.12.011 Kelly, 2018, Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States, Eur Urol Focus., 4, 121, 10.1016/j.euf.2017.10.014 Prostate cancer fact sheet. https://gco.iarc.fr/today/data/factsheets/cancers/27-Prostate-fact-sheet.pdf. Updated December, 2020. Accessed on February 19, 2021. Chevalme Y, Boudali L, Gauthé M, et al. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68 Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18 F-fluorocholine PET/CT: 1084 examinations. Eur J Nucl Med Mol Imaging. Jan 8, 2021 [Online ahead of print]. Marzec, 2020, 68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases of recurrent prostate cancer after initial surgery, Acta Oncol., 59, 149, 10.1080/0284186X.2019.1669816 Cattrini C, Zanardi E, Boccardo F. Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer. J Clin Oncol. 2018;36:2350. Kneebone, 2018, Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography, Eur Urol Oncol., 1, 531, 10.1016/j.euo.2018.04.017 Cui, 2020, Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients, World J Clin Cases., 8, 54, 10.12998/wjcc.v8.i1.54